Navigation Links
NeuroVasx Receives Canadian Approval for cPAX Aneurysm Treatment System
Date:8/27/2009

MAPLE GROVE, Minn., Aug. 27 /PRNewswire/ -- NeuroVasx, Inc., a medical device company that develops technologies for the treatment of hemorrhagic and ischemic stroke, announced today that it has received approval to market its cPAX Aneurysm Treatment System in Canada from Health Canada's Therapeutic Products Directorate. In addition to Canadian regulatory approval, the cPAX System also received CE Mark in March 2009.

Eric B. Timko, President and Chief Executive Officer of NeuroVasx, said, "This approval allows for our first commercial entry into the North American market and is another milestone in our effort to expand patient access to the cPAX System. We continue to work with the FDA on our 510(k) submission for cPAX and look forward to potential US regulatory approval and commercialization in the near future. We look forward to commercialization of cPAX to address the $450 million worldwide endovascular neurological device market."

The cPAX System is a minimally invasive device for the embolization of cerebral aneurysms, abnormal bulges or sacs in the wall of an artery in the brain. If ruptured, aneurysms can result in massive intracranial bleeding and often lead to death.

cPAX is a polymer strand delivered through a microcatheter using the same delivery technique as the currently used platinum coil technology. cPAX was designed to achieve more complete filling of the aneurysm using fewer devices and provide the physician the ability to detach the device at any point versus the fixed detachment zone common to platinum coils. The polymeric material also allows for non-invasive CT and MRI scans free of metallic artifact for a more accurate patient follow-up assessment.

Mr. Timko continued, "We believe that physicians in Canada will appreciate the cPAX System's ability to achieve superior aneurysm filling, especially in large aneurysms, along with its shorter procedure times and greater imaging qualities. The system will be particularly beneficial to Canadian patients with large cerebral aneurysms greater than 10 millimeters in diameter, for which current minimally invasive treatment options are often ineffective because of inadequate aneurysm filling. The inherent characteristics of the cPAX polymer are ideally suited to easily take on the shape of these aneurysms, maximizing packing of the material and leading to better outcomes."

About Cerebral Aneurysms

A cerebral aneurysm is an abnormal bulge or sac in the wall of an artery in the brain which can be caused by a number of factors including congenital defects, high blood pressure, atherosclerosis, cancer, drug use or head trauma. If a cerebral aneurysm ruptures, it can lead to a hemorrhagic stroke, or bleeding on the brain. According to National Institutes of Health, approximately 40% of these patients do not survive the first 24 hours. The worldwide incidence of cerebral aneurysms is estimated to be 320,000 annually, approximately 200,000 of which may be treatable with intracranial surgery or minimally invasive techniques.

About NeuroVasx, Inc.

NeuroVasx, Inc. (http://www.neurovasx.com/) is a privately held medical device company located in Maple Grove, MN. The company is dedicated to the development and commercialization of technologies for the minimally invasive treatment of hemorrhagic and ischemic stroke. The worldwide market potential for stroke treatment devices is estimated to be over $3 billion.

    Contact:                           Media Contacts:
    Eric B. Timko                      Jason Rando / Jennifer Saunders
    President and CEO                  The Ruth Group
    NeuroVasx                          646-536-7025 / 646-536-7011
    763-315-0013                       jrando@theruthgroup.com
                                       jsaunders@theruthgroup.com


'/>"/>
SOURCE NeuroVasx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NeuroVasx Receives CE Mark for cPAX Aneurysm Treatment System
2. Spinal Implant Developed by Sanford Clinic Neurosurgeon Receives FDA 510(k) Market Clearance as a Lumbar Intervertebral Body Fusion Device
3. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
4. Fox Insurance Company Receives Excellent Ratings for Customer Service From The Centers for Medicare & Medicaid Services
5. Cambrex Receives FDA Warning Letter
6. NovoLogix, Inc. Receives EHNAC Healthcare Network Accreditation
7. Ranbaxy Receives Final Approval to Manufacture and Market Glycopyrrolate Tablets
8. vProtect Luminal Shield (TM) from Prescient Medical Receives CE Mark
9. Integrated Medical Systems Receives $1.1 Million From the U.S. Department of Defense for Critical Enhancements of the Worlds First Suitcase Intensive Care Unit
10. EndyMed Medical Receives FDA Clearance for Painless, Non-invasive Anti-Wrinkle Treatment System
11. Sound Pharmaceuticals Receives an Office of Naval Research Award for Its Hearing Loss Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: